和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 09-30 16:08:27

13.860

+0.320

+2.36%

最高14.360	最低13.580	成交量993.50万
今开13.580	昨收13.540	日振幅5.76%
总市值120.44亿	流通市值120.44亿	总股本8.69亿
成交额1.39亿	换手率1.14%	流通股本8.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":13.86,"timestamp":1790755707003,"preClose":13.54,"halted":0,"volume":9935000,"delay":0,"changeRate":0.023633677991137393,"floatShares":869000000,"shares":869000000,"eps":0.11,"marketStatus":"未开盘","change":0.32,"latestTime":"09-30 16:08:27","open":13.58,"high":14.36,"low":13.58,"amount":138862526,"amplitude":0.057607,"askPrice":13.87,"askSize":11000,"bidPrice":13.86,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":0.762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":13.54,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":0.9537993972646244,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"1115327866","title":"异动解读｜和铂医药-B盘中上涨5.1%，AI抗体语言模型及多重利好持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1115327866","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115327866?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:37","pubTimestamp":1790735840,"startTime":"0","endTime":"0","summary":"9月30日，和铂医药-B盘中上涨5.1%，报14.23港元，成交额3988.69万港元。消息面上，公司近期利好密集释放。全资附属公司诺纳生物成功开发全球首个基于全人源仅重链抗体训练的语言模型HCAbLM，标志着公司在AI驱动抗体发现领域取得重要进展。上半年公司实现营收1.22亿美元，同比增长20.9%，毛利率高达95.24%，平台型战略持续兑现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药盘中上扬，AI抗体模型利好催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149716901","title":"异动解读｜和铂医药-B盘中下跌5.31%，生物科技板块集体走弱叠加前期涨幅回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1149716901","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149716901?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:23","pubTimestamp":1790216595,"startTime":"0","endTime":"0","summary":"9月24日，和铂医药-B盘中下跌5.31%，报14.43港元，成交额3605.82万港元。公司所在生物科技板块今日集体承压，荣昌生物跌6.22%、三生制药跌3.88%、康方生物跌3.69%、信达生物跌3.63%、百济神州跌1.56%，行业整体情绪偏弱。短期密集利好兑现后，叠加板块整体回调，股价出现获利回吐压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技板块集体走弱，和铂医药承压回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06160","01877","01801","LU0029874061.USD","LU0348735423.USD","LU0516423091.SGD","LU2097828805.USD","IBBQ","02142","LU0417516902.SGD","LU1719994722.HKD","LNGR","LU1993786604.SGD","LU0348784397.USD","LU1152091754.HKD","09995","09926","LU0359202008.SGD","MEDX","LU1251922891.USD","06978","LU2039709279.SGD","LU1770034418.SGD","LU0828237510.HKD","LU0128526141.USD","KCE","LU1226287792.SGD","01093","06185","LU2476274720.SGD","02269","01177","LU0315179316.USD","BK1515","LU0039217434.USD","HK0000165453.HKD","KURE","LU0708995583.HKD","09688","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","SG9999002562.SGD","LU3063872942.SGD","02616","LU1226288253.USD","600109","LU1152091168.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188319718","title":"异动解读｜和铂医药-B盘中上涨7.4%，多重利好持续催化股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1188319718","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188319718?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:33","pubTimestamp":1789954401,"startTime":"0","endTime":"0","summary":"9月21日，和铂医药-B盘中上涨7.4%，报14.53港元，成交额2025.04万港元，延续近期强势表现。消息面上，公司近期利好密集释放。全资附属公司诺纳生物于9月16日宣布成功开发HCAbLM——全球首个基于全人源仅重链抗体训练的语言模型，标志着AI在抗体发现与开发领域的重要突破，该消息持续催化市场情绪。上半年公司收入1.22亿美元，同比增长20.9%，基本面持续向好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AI抗体突破，和铂医药强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67%     AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","BK1237","03033","BK1193","07552","LU1235295612.USD","LU0128522157.USD","BK1141","HHImain","01787","LU0672654166.SGD","IE0003895053.USD","LU0264606111.USD","LNVGY","LU1267930227.SGD","BK1607","02701","LU0244354667.USD","BK1576","HK0000320223.HKD","03696","BK1617","600547","00100","09067","BK1592","LU0572939691.SGD","LU1831875114.USD","06658","02670","03419","LU1808992512.USD","BK1161","LU1046422090.SGD","BK1583","BK1198","02837","BK1117","07630","03417","02228","03088","03115","00992","02142","IE0032431581.USD","LU1366334578.USD","603127","02800","03423","LU0417516902.SGD","LU0572940350.SGD","300077","LU0181495838.USD","82800","83115","LU0049112450.USD","LU0972618739.USD","LU0862451753.SGD","LU0326950275.SGD","LU0828237940.HKD","IE0034224299.USD","IE00B0JY6N72.USD","LU1188198961.HKD","BK1163","06127","LU0862451837.USD","07226","LU0370786039.SGD","HK0000320264.USD","TCHI","LU0029875118.USD","01300","LU0543330483.HKD","BK1506","LU0348825331.USD","LU0348827113.USD","09088","LU0791590937.USD","01818","LU0140636845.USD","LU0791591158.USD","07500","LU2242644610.SGD","LU0048580855.USD","03067","01879","MCHmain","07200","HK0000306701.USD","07666","02656","09115","BK1149","09903","BK1574","BK1544","03037","HSTECH","LU0890818403.SGD","LU0320764755.SGD","LU0128525689.USD","07300","BK1526","LU1366334651.USD","BK1183","HSI","LU0463099449.HKD","80992","02833","HK0000306685.HKD","LU0052756011.USD","03032","LU1785774172.SGD","513600","LU0561508036.HKD","LU0310800965.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919445","title":"港股异动 | 生物医药股悉数走高 十部门印发医药十五五规划 机构看好医药迎“Claude”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919445","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919445?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:04","pubTimestamp":1789697085,"startTime":"0","endTime":"0","summary":"消息面上，工信部等十部门联合发布《医药工业发展\"十五五\"规划》，提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。浙商证券表示，高频迭代短期将会带来验证阶段需求的井喷，但长期来看，高速迭代可能会带来平台能力的提升和泛化，能够持续迭代的发现平台能力提升或是行业的核心，医药行业的Claude也许将要到来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","09939","BK4585","KCAI","02142","BK1515","BK1588","VXUS","BK1141","BK1583","399441","06127","161726","BK4581","01672","XBI","07666","BK4588","BK1576","LU2488822045.USD","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148016998","title":"异动解读｜和铂医药-B盘中上涨5.2%，子公司开发全球首个全人源重链抗体语言模型持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1148016998","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148016998?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:36","pubTimestamp":1789695411,"startTime":"0","endTime":"0","summary":"9月18日，和铂医药-B盘中上涨5.2%，报13.54港元，成交额1547.55万港元，延续前一交易日涨势。消息面上，公司全资附属公司诺纳生物近日宣布成功开发HCAbLM——全球首个基于全人源仅重链抗体训练的语言模型。此外，公司9月7日已正式纳入恒生综合指数并进入港股通标的，有助于拓宽股东基础及提升流动性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药盘中上涨，全球首创抗体模型催化","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668937224","title":"港股异动 | 和铂医药-B(02142.HK)早盘涨近5% 附属诺纳生物成功开发HCAbLM训练语言模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2668937224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668937224?lang=zh_cn&edition=full","pubTime":"2026-09-17 09:37","pubTimestamp":1789609074,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118542582","title":"和铂医药-B披露子公司开发全球首个全人源HCAb语言模型","url":"https://stock-news.laohu8.com/highlight/detail?id=1118542582","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118542582?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:07","pubTimestamp":1789553251,"startTime":"0","endTime":"0","summary":"2026年9月16日，和铂医药-B发布自愿公告称，其全资附属公司诺纳生物成功开发全球首个基于全人源仅重链抗体训练的语言模型HCAbLM。研究结果表明，HCAbLM学习到了与仅重链抗体形式相关的独特序列“语法”，并揭示了传统抗体语言模型无法充分捕获的序列模式及其相互关系。和铂医药-B指出，HCAbLM的开发标志着诺纳生物在将人工智能应用于抗体发现与开发领域取得重要进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667604086","title":"和铂医药-B(02142.HK)：诺纳生物成功开发全球首个基于全人源仅重链抗体的语言模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2667604086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667604086?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:02","pubTimestamp":1789552947,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146604158","title":"和铂医药-B旗下诺纳生物推出全球首个全人源重链抗体语言模型HcaBLM","url":"https://stock-news.laohu8.com/highlight/detail?id=1146604158","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146604158?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:02","pubTimestamp":1789552930,"startTime":"0","endTime":"0","summary":"和铂医药-B旗下诺纳生物近日宣布，成功开发出HcaBLM——这一全球首创的语言模型，专门面向全人源重链抗体领域。HcaBLM能够精准解析并生成全人源重链抗体的序列信息，为药物研发提供强大助力。业内观察人士指出，这一进展不仅彰显了和铂医药-B在抗体技术领域的领先地位，也为整个行业开辟了全新的研发路径。随着该模型的进一步应用，全人源重链抗体的开发周期有望大幅缩短，治疗性抗体的可及性也将随之提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116582767","title":"异动解读｜和铂医药-B盘中下跌5.34%，中期盈利及现金流承压叠加生物科技板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1116582767","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116582767?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:59","pubTimestamp":1789527589,"startTime":"0","endTime":"0","summary":"9月16日，和铂医药-B盘中下跌5.34%，报12.05港元，成交额3017.67万港元，延续前一交易日跌势。消息面上，公司此前披露中期业绩显示，上半年营收1.22亿美元同比增长20.9%，但净利润6485.1万美元同比下降11.16%，经营活动现金流由上年同期净流入6166.4万美元转为净流出1434.3万美元，盈利质量承压。机构研报指出，公司合作收入占比超九成，业绩可能随交易及收入确认节奏波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和铂医药盘中走低，盈利与现金流承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148029589","title":"异动解读｜和铂医药-B盘中下跌5.31%，生物科技板块整体走弱叠加中期利润及现金流承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1148029589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148029589?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:39","pubTimestamp":1789457982,"startTime":"0","endTime":"0","summary":"9月15日，和铂医药-B盘中下跌5.31%，报12.67港元，成交额1.17亿港元。消息面上，公司此前披露中期业绩显示，上半年营收1.22亿美元同比增长20.9%，但净利润6485.1万美元同比下降11.16%，经营活动现金流由上年同期净流入6166.4万美元转为净流出1434.3万美元，盈利质量承压。中金研报亦指出，合作收入占比超九成，业绩可能随交易及收入确认节奏波动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和铂医药盘中走低，现金流承压拖累情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189672893","title":"异动解读｜和铂医药-B盘中下跌5.21%，生物科技板块整体走弱叠加中期利润承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1189672893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189672893?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:09","pubTimestamp":1789092586,"startTime":"0","endTime":"0","summary":"9月11日，和铂医药-B盘中下跌5.21%，报13.45港元，成交额4545.73万港元。板块层面，生物科技行业今日普遍走弱，信达生物跌2.54%、康方生物跌2.14%、百济神州跌1.84%、剂泰科技-P跌6.44%。个股方面，公司此前披露中期业绩显示，上半年营收1.22亿美元同比增长20.9%，但净利润6485.1万美元同比下降11.16%，经营活动现金流由净流入6166.4万美元转为净流出1434.3万美元，盈利质量承压。此外，南向资金近20个交易日累计净减持近100万股，资金面偏谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和铂医药盘中走弱，盈利质量承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165163565","title":"和铂医药-B2026年中期营收1.22亿美元，净利润6,485.1万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165163565","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165163565?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:43","pubTimestamp":1789047793,"startTime":"0","endTime":"0","summary":"根据公司最新发布的2026年中期业绩公告，和铂医药-B报告期实现营收1.22亿美元，同比上涨20.9%。从毛利来看，期内毛利约1.17亿美元，对应毛利率约95.24%。成本结构方面，销售成本约为585.3万美元，同比增长约20.6%，主要与报告期内营收增加及研究服务费用增长有关。报告期内经营活动产生的现金流由上年同期净流入6,166.4万美元转为净流出1,434.3万美元。（报告期内暂无可引用的管理层直接发言。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B2026年中期营收1.22亿美元，净利润6,485.1万美元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","06160","01093","LU0417516738.SGD","LU0181495838.USD","09926","KCE","06185","LU1226287792.SGD","LU1813983027.USD","LU0979878070.USD","LU2148510915.USD","LU1961090484.USD","06030","LU1969619763.USD","LU2580892862.HKD","LU0405327494.USD","LU1064130708.USD","LU0819121731.USD","LU1794554557.SGD","BK1161","LU1880383366.USD","09995","LU0463099449.HKD","LU1820825898.SGD","LU0348783233.USD","LU0348825331.USD","LU1655091616.SGD","02616","01877","IE0008369823.USD","09688","LU1255011170.USD","LU0516422952.EUR","LU1997245177.USD","BK1141","01801","KURE","IE00B543WZ88.USD","SG9999004220.SGD","LU0561508036.HKD","LU2039709279.SGD","LU1580142542.USD","BK0028","02269","02142","01177","LU0572944931.SGD","LU1226287875.USD","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666295555","title":"和铂医药：BD进入“复利时刻”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666295555","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666295555?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:19","pubTimestamp":1788999594,"startTime":"0","endTime":"0","summary":"中国创新药BD出海正在经历一场质变。","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6581147","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132556829","title":"和铂医药-B旗下Solstice Oncology启动2.25亿美元A轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1132556829","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132556829?lang=zh_cn&edition=full","pubTime":"2026-09-09 23:21","pubTimestamp":1788967293,"startTime":"0","endTime":"0","summary":"9月9日，路透社消息——和铂医药-B（2142.HK）今日公告，其旗下Solstice Oncology正式启动A轮融资，规模高达2.25亿美元。此举标志着该公司在肿瘤治疗领域的战略布局迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133473068","title":"和铂医药-B：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并启动运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1133473068","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133473068?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:15","pubTimestamp":1788952531,"startTime":"0","endTime":"0","summary":"2026年9月9日，和铂医药-B发布自愿公告称，其合作伙伴Solstice Oncology已完成2.25亿美元A轮融资并正式启动运营。本轮融资由RA Capital Management领投，Canaan Partners、Forbion及其他投资者共同参与。Solstice Oncology是一家临床阶段的肿瘤免疫公司，专注于新辅助治疗领域，成立于2026年2月。截至本公告日，和铂医药-B董事会成员包括执行董事王劲松博士、陈侑晨先生、刘毅博士，以及独立非执行董事Robert Irwin Kamen博士、叶小平博士、Albert R. Collinson博士和陈维维女士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587444","title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587444","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666587444?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:13","pubTimestamp":1788952398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司的合作伙伴公司Solstice Oncology 已完成2.25亿美元的A轮融资并正式启动运营。Solstice是一家临床阶段的肿瘤免疫公司，致力于在新辅助治疗阶段更早地干预癌症。MSS型是结肠癌中占比最大的亚型，迄今为止该患者群体仍未能从免疫治疗中获益。该2期临床试验预计将于 2026年第四季度初启动患者入组，并预期将于2027年下半年取得该研究数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0906},{"period":"1month","weight":-0.0184},{"period":"3month","weight":0.2845},{"period":"6month","weight":-0.0422},{"period":"1year","weight":-0.1166},{"period":"ytd","weight":0.1398}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.031233},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057848},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}